Details for New Drug Application (NDA): 209839
✉ Email this page to a colleague
The generic ingredient in SOLIFENACIN SUCCINATE is solifenacin succinate. There are thirty drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the solifenacin succinate profile page.
Summary for 209839
Tradename: | SOLIFENACIN SUCCINATE |
Applicant: | Cipla |
Ingredient: | solifenacin succinate |
Patents: | 0 |
Pharmacology for NDA: 209839
Mechanism of Action | Cholinergic Muscarinic Antagonists |
Medical Subject Heading (MeSH) Categories for 209839
Suppliers and Packaging for NDA: 209839
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 209839 | ANDA | Cipla USA Inc. | 69097-259 | 69097-259-02 | 30 TABLET in 1 BOTTLE (69097-259-02) |
SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 209839 | ANDA | Cipla USA Inc. | 69097-259 | 69097-259-05 | 90 TABLET in 1 BOTTLE (69097-259-05) |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 5MG | ||||
Approval Date: | May 20, 2019 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 10MG | ||||
Approval Date: | May 20, 2019 | TE: | RLD: | No |
Complete Access Available with Subscription